What does “Prolia ONJ” mean?
“Prolia ONJ” usually refers to osteonecrosis of the jaw (ONJ) occurring in people taking Prolia (denosumab) for osteoporosis or other bone conditions. ONJ is a known, uncommon but serious side effect. [1]
How common is ONJ with Prolia?
Prolia-related ONJ is rare, but the risk is higher in people with certain risk factors such as invasive dental procedures (like extractions), poor oral health, and long-term use of antiresorptive medicines. The exact rate depends on dose history, duration, and the underlying indication. [1]
Who is more likely to get ONJ from Prolia?
Risk increases with factors that can worsen jaw bone healing or increase exposure to antiresorptive drugs, including:
- Tooth extractions or other invasive dental work
- Poor oral hygiene, existing dental disease, or ill-fitting dentures
- Longer treatment duration with bone-protecting medications
- Other medical risks that affect healing (for example, cancer therapies and corticosteroid use are often implicated in ONJ risk discussions)
A dentist and the prescribing clinician typically assess these before starting or continuing therapy. [1]
What symptoms should patients watch for?
People concerned about ONJ are usually told to watch for signs such as:
- Jaw pain or swelling
- Loose teeth
- Non-healing sores or exposed bone in the mouth
- Poorly healing after dental work
If these occur, the patient should contact their dentist or doctor promptly. [1]
Can you get dental procedures while on Prolia?
Dental planning is important because ONJ risk rises after invasive dental procedures. Many clinicians coordinate care before starting denosumab and before planned extractions or implants, aiming to minimize trauma and ensure good oral health. Decisions are individualized based on ONJ history, urgency of dental work, and cancer vs osteoporosis context. [1]
Is ONJ treatable if it happens?
ONJ treatment usually focuses on controlling infection/inflammation, supporting oral hygiene, and managing symptoms. The plan can vary from conservative care to surgical approaches depending on severity. Early detection generally leads to better outcomes. [1]
Prolia vs similar drugs: does “ONJ” risk differ?
ONJ is also associated with other antiresorptive therapies (for example, bisphosphonates). For Prolia specifically, ONJ risk is described in labeling and risk assessments, but rates can differ by drug, dosing schedule, treatment duration, and patient risk profile. [1]
When should someone stop Prolia because of ONJ concerns?
Stopping or delaying Prolia is a medical decision that depends on whether ONJ has already occurred, how severe it is, the reason for treatment, and the patient’s fracture risk. Because stopping denosumab can affect bone density, patients should not make changes without their prescriber. [1]
Sources:
[1] https://www.accessdata.fda.gov/ (FDA Prolia prescribing information; includes osteonecrosis of the jaw risk information)